Prosecutors on Friday called for an 18-year prison sentence for Keisuke Yoshida, a 42-year-old former employee of pharmaceutical giant Daiichi Sankyo, who is on trial for the methanol poisoning ...

Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells. The drugmaker has teamed up with ...

Daiichi Sankyo has succeeded in a bid to convince the US Patent and Trademark Office (PTO) to take another look at a patent held by Seagen that was previously deemed to have been infringed by its ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine Approval would give Japan a home-grown mRNA vaccine of the type that has made up the bulk of its COVID inoculations so far.

Daiichi Sankyo Co. said on Friday it submitted its mRNA-based COVID-19 vaccine for regulatory approval in Japan. Approval would give Japan a home-grown mRNA vaccine of the type that have made up ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Dividend history information is presently unavailable for this company. This could indicate that the company has never provided a dividend or that a dividend is pending. Nasdaq Data provided by ...